EQUILLIUM, INC. (EQ) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -19.30M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-19.30M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-20.37M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-23.63M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $-24.37M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-20.48M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-14.35M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-8.27M | $41.09M | (m) | (m) | (m) | -20.12% |
| 2024-09-30 | $-6.77M | $45.91M | (m) | (m) | (m) | -14.75% |
| 2024-06-30 | $-9.71M | $42.62M | (m) | (m) | (m) | -22.79% |
| 2024-03-31 | $-13.21M | $37.89M | (m) | (m) | (m) | -34.85% |
| 2023-12-31 | $-14.52M | $36.08M | (m) | $37.04M | (m) | -40.24% |
| 2023-09-30 | $-9.28M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-18.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-28.86M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-62.08M | $15.76M | (m) | $37.55M | (m) | -393.91% |
| 2022-09-30 | $-74.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-71.13M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-66.42M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-37.79M | (m) | (m) | $26.38M | (m) | (m) |
| 2021-09-30 | $-36.37M | (m) | (m) | $25.40M | (m) | (m) |
| 2021-06-30 | $-33.02M | (m) | (m) | $22.65M | (m) | (m) |
| 2021-03-31 | $-30.79M | (m) | (m) | $20.56M | (m) | (m) |
| 2020-12-31 | $-29.55M | (m) | (m) | $19.38M | (m) | (m) |
| 2020-09-30 | $-28.19M | (m) | (m) | $18.27M | (m) | (m) |
| 2020-06-30 | $-28.00M | (m) | (m) | $18.23M | (m) | (m) |
| 2020-03-31 | $-27.83M | (m) | (m) | $18.59M | (m) | (m) |
| 2019-12-31 | $-26.73M | (m) | (m) | $17.64M | (m) | (m) |
| 2019-09-30 | $-23.34M | (m) | (m) | $14.71M | (m) | (m) |
| 2019-06-30 | $-19.24M | (m) | (m) | $11.75M | (m) | (m) |
| 2019-03-31 | $-13.93M | (m) | (m) | $8.04M | (m) | (m) |
| 2018-12-31 | $-8.62M | (m) | (m) | $4.94M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |